TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04740203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CD19 and CD22
Description: Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
Study: NCT05797792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial alteplase
Description: See arm/group descriptions.
Study: NCT05022095

Intervention type: OTHER
Intervention: Questionnaires
Description: Diverse questionnaires have to be filled in.
Study: NCT05957302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
Study: NCT05713006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib Oral Product
Description: Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
Study: NCT05870956

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT05444725

Intervention type: OTHER
Group type: OTHER
Intervention: Stage of Decision Making
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Choice framing
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Opportunity Framing
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
Study: NCT06038344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free food guide teaching
Description: Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
Study: NCT05494008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean herbal medicine treatment
Description: Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Korean herbal medicine treatment
Description: acupuncture, pharmacoacupuncture, cupping, chuna
Study: NCT05045027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo multinuclear metabolic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04964544

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 5 mg rosuvastatin calcium with a Web App (combination product)
Description: The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
Study: NCT05495152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
Study: NCT04715542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stibium metallicum praeparatum 6x
Description: Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Study: NCT05945615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% (Pf) Oph Soln Ud
Description: Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free lubricating drops
Description: Over the counter ophthalmic lubricating drop.
Study: NCT05156762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Patients randomized to the bariatric surgery study arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass - this decision would be a joint decision made between the study participant and the bariatric surgeon after consideration of the patient's overall goals with weight loss and discussion of the risks and benefits of each procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical weight loss
Description: Study participants randomized to the medical weight loss study arm will have consultations with nutritionists, dieticians, and endocrinologists, and will make dietary and lifestyle changes in an effort to lower their BMI to ≤ 40 kg/m2. Patients may also be placed on pharmacotherapy to assist with weight loss.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient research surveys
Description: Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient research surveys
Description: Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total joint arthroplasty (TJA)
Description: Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.
Study: NCT04953338

Intervention type: OTHER
Intervention: Exposure of mental health condtion of interest
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.

Intervention type: OTHER
Intervention: Exposure of mental health condtion of interest
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
Study: NCT05008029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ immobilization
Description: Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction under general anesthesia
Description: The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
Study: NCT05156762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total joint arthroplasty (TJA)
Description: Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total joint arthroplasty (TJA)
Description: Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual standard of care
Description: Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics. They will be urged to make an appointment or to seek any other interventions they choose to help lower their BMI, but no appointments will be made for them. A follow up visit in 6 months and 1 year will be made for them in the arthroplasty clinic to reassess their progress. Referral information will again be provided at 6 months if no progress has been made.
Study: NCT04958707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information including knowledge and skills related to dementia patient care
Description: The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
Study: NCT06137742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07868489
Description: Experimental Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-07868489
Description: Placebo
Study: NCT05370586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve Group Block
Description: Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
Study: NCT06065384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group: intensive motor training
Description: Intervention group: receive an extra 12 hours of motor training each week (distributed over the week) for 10 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
Study: NCT05370586

Intervention type: OTHER
Group type: OTHER
Intervention: Infrainguinal Fascia Iliaca Block
Description: Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
Study: NCT06647667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIITS
Description: Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.~session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.~Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down
Study: NCT05212662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator supplied in vials identical to the active intervention, TTI-0102
Study: NCT05757427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelia #2
Description: Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
Study: NCT06126029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 Mg extended release Oral Tablet
Description: 34 patients of experimental group will get metformin 500mg extended release oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 34 patients of placebo group will get placebo oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
Study: NCT06514040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Precedex
Description: Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to anaesthesia and surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 25 mg
Description: Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain (as substance -p), nausea, and other symptoms of migraine
Study: NCT05584540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UNTIRE App
Description: Digital therapeutic application
Study: NCT06065384

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual rehabilitation
Study: NCT05629611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vi-Sealer
Description: using Reusable device, Vi-Sealer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vi-Sealer
Description: using Reusable device, Vi-Sealer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure
Description: using Ligasure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other AHD
Description: Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
Study: NCT06181929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low dose CT
Description: A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
Study: NCT05239494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DT1 Sphere Contact Lenses
Description: Devices: Dailies Total 1 Sphere Contact Lenses
Study: NCT05600270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angled guidewire
Description: Cannulation of the common bile duct using an angled-tip guidewire during ERCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straight guidewire
Description: Cannulation of the common bile duct using an straight-tip guidewire during ERCP
Study: NCT06342401

Intervention type: DIAGNOSTIC_TEST
Intervention: ENCODE
Description: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: ENCODE
Description: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: ENCODE
Description: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: ENCODE
Description: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.
Study: NCT06285214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 1 mg - 1 tablet taken orally at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study: NCT06585514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study: NCT06095557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sponsor MCG device
Description: unshielded device measuring cardiac magnetic fields
Study: NCT06439641

Intervention type: OTHER
Group type: OTHER
Intervention: Ulcerative colitis Disease Activity Index
Description: QUESTIONNAIRE - Score between 0 to 12, the higher is the worse
Study: NCT04981691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MESO CAR T cells
Description: Autologous genetically modified anti-MESO CAR T cells
Study: NCT06284863

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Natritional Education Program In Hemodialysis Patients
Description: Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
Study: NCT05201911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-AT03
Description: IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.